These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 16510182)

  • 1. Novel valproic acid derivatives with potent differentiation-inducing activity in myeloid leukemia cells.
    Deubzer H; Busche B; Rönndahl G; Eikel D; Michaelis M; Cinatl J; Schulze S; Nau H; Witt O
    Leuk Res; 2006 Sep; 30(9):1167-75. PubMed ID: 16510182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
    Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G
    Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS; Liu DS; Dai CW; Li RJ
    Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
    Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
    Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valproic acid exerts differential effects on CXCR4 expression in leukemic cells.
    Gul H; Marquez-Curtis LA; Jahroudi N; Larratt LM; Janowska-Wieczorek A
    Leuk Res; 2010 Feb; 34(2):235-42. PubMed ID: 19539992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
    Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
    Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
    Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia.
    Cheng YC; Lin H; Huang MJ; Chow JM; Lin S; Liu HE
    Leuk Res; 2007 Oct; 31(10):1403-11. PubMed ID: 17445886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproic acid for the treatment of myeloid malignancies.
    Kuendgen A; Gattermann N
    Cancer; 2007 Sep; 110(5):943-54. PubMed ID: 17647267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silencing of membrane-associated sialidase Neu3 diminishes apoptosis resistance and triggers megakaryocytic differentiation of chronic myeloid leukemic cells K562 through the increase of ganglioside GM3.
    Tringali C; Lupo B; Cirillo F; Papini N; Anastasia L; Lamorte G; Colombi P; Bresciani R; Monti E; Tettamanti G; Venerando B
    Cell Death Differ; 2009 Jan; 16(1):164-74. PubMed ID: 18820643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells.
    Ozpolat B; Akar U; Steiner M; Zorrilla-Calancha I; Tirado-Gomez M; Colburn N; Danilenko M; Kornblau S; Berestein GL
    Mol Cancer Res; 2007 Jan; 5(1):95-108. PubMed ID: 17259349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PKC pathway and ERK/MAPK pathway are required for induction of cyclin D1 and p21Waf1 during 12-o-tetradecanoylphorbol 13-acetate-induced differentiation of myeloleukemia cells.
    Matsumoto E; Hatanaka M; Bohgaki M; Maeda S
    Kobe J Med Sci; 2006; 52(6):181-94. PubMed ID: 17329956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines.
    Savickiene J; Borutinskaite VV; Treigyte G; Magnusson KE; Navakauskiene R
    Eur J Pharmacol; 2006 Nov; 549(1-3):9-18. PubMed ID: 16978604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells.
    Fortunati N; Bertino S; Costantino L; Bosco O; Vercellinatto I; Catalano MG; Boccuzzi G
    Cancer Lett; 2008 Feb; 259(2):156-64. PubMed ID: 18006146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.
    Neri P; Tagliaferri P; Di Martino MT; Calimeri T; Amodio N; Bulotta A; Ventura M; Eramo PO; Viscomi C; Arbitrio M; Rossi M; Caraglia M; Munshi NC; Anderson KC; Tassone P
    Br J Haematol; 2008 Nov; 143(4):520-31. PubMed ID: 18986388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia.
    Cimino G; Lo-Coco F; Fenu S; Travaglini L; Finolezzi E; Mancini M; Nanni M; Careddu A; Fazi F; Padula F; Fiorini R; Spiriti MA; Petti MC; Venditti A; Amadori S; Mandelli F; Pelicci PG; Nervi C
    Cancer Res; 2006 Sep; 66(17):8903-11. PubMed ID: 16951208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel valproic acid derivatives with hemoglobin F inducing activity.
    Rönndahl G; Mönkemeyer S; Schulze S; Pekrun A; Eikel D; Nau H; Witt O
    Am J Hematol; 2006 May; 81(5):374-6. PubMed ID: 16628726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M; Nguyen TK; Dent P; Grant S
    Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of neutrophilic differentiation of human promyelocytic leukemic cells by branched-chain carboxylic acid anticonvulsant drugs.
    Fischkoff SA; Walter E
    J Biol Response Mod; 1984; 3(2):132-7. PubMed ID: 6427413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.